News

myMatrixx Chief Client Officer, Paul King, continues the conversation on the power of trust.

myMatrixx Chief Sales Officer, David Dubrof, discusses how PBMs should be working to build trust with clients from day one.

The U.S. Food and Drug Administration (FDA) fully approved the first vaccine for active prevention of COVID-19 in individuals 16 years of age and older.

myMatrixx parent company Cigna has established new requirements to help protect its workforce.

A recent post from a myMatrixx client highlights our ongoing partnership to deliver safe and cost-effective drug therapy through careful prescription monitoring.

On August 12, 2021, the FDA updated the Emergency Use Authorization (EUA) for the COVID-19 vaccines from Moderna and Pfizer/BioNTech.

On July 16, myMatrixx Chief Clinical Officer Phil Walls will speak to the Kansas Self Insurers Association’s (KSIA) Annual Conference.

myMatrixx Chief Clinical Officer Phil Walls joined John Ruser, PhD, President and CEO of the Workers’ Compensation Research Institute for an on-demand webinar available starting June 24, on the Risk & Insurance website.

The COVID-19 pandemic will continue to have an impact on workers’ compensation pharmacy for the foreseeable future. Recently, myMatrixx Vice President of Business Intelligence, Cliff Belliveau, joined Chief Clinical Officer, Phil Walls, to discuss this new landscape for industry publication Risk & Insurance’s Insights feature.

In a new post for industry publication WorkCompWire, myMatrixx Chief Clinical Officer Phil Walls shares how the COVID-19 pandemic will have a lasting effect on workers’ compensation pharmacy.